Free Trial
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alumis Inc. stock logo
ALMS
Alumis
$7.16
+2.7%		$15.31
$4.28
▼
$31.35
$926.75M-0.382.94 million shs1.37 million shs
InflaRx N.V. stock logo
IFRX
InflaRx
$1.60
+4.6%		$1.99
$0.80
▼
$2.95
$235.79M2.59521,799 shs740,708 shs
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$10.60
+0.8%		$11.36
$7.36
▼
$13.90
$942.99M0.471.80 million shs1.47 million shs
ODTX
Odyssey Therapeutics
$19.00
+4.9%		$22.76
$15.10
▼
$29.05
$913.12MN/A427,235 shs325,591 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alumis Inc. stock logo
ALMS
Alumis
0.00%+4.53%-27.68%-74.71%+61.63%
InflaRx N.V. stock logo
IFRX
InflaRx
0.00%-6.98%-21.95%-21.95%+8.84%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
0.00%-0.47%-8.38%-7.42%+5.16%
ODTX
Odyssey Therapeutics
0.00%-8.35%-19.63%+13.84%+1,899,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alumis Inc. stock logo
ALMS
Alumis
$7.16
+2.7%		$15.31
$4.28
▼
$31.35
$926.75M-0.382.94 million shs1.37 million shs
InflaRx N.V. stock logo
IFRX
InflaRx
$1.60
+4.6%		$1.99
$0.80
▼
$2.95
$235.79M2.59521,799 shs740,708 shs
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$10.60
+0.8%		$11.36
$7.36
▼
$13.90
$942.99M0.471.80 million shs1.47 million shs
ODTX
Odyssey Therapeutics
$19.00
+4.9%		$22.76
$15.10
▼
$29.05
$913.12MN/A427,235 shs325,591 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alumis Inc. stock logo
ALMS
Alumis
0.00%+4.53%-27.68%-74.71%+61.63%
InflaRx N.V. stock logo
IFRX
InflaRx
0.00%-6.98%-21.95%-21.95%+8.84%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
0.00%-0.47%-8.38%-7.42%+5.16%
ODTX
Odyssey Therapeutics
0.00%-8.35%-19.63%+13.84%+1,899,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alumis Inc. stock logo
ALMS
Alumis
2.86
Moderate Buy$33.27364.70% Upside
InflaRx N.V. stock logo
IFRX
InflaRx
2.67
Moderate Buy$7.43364.29% Upside
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
2.77
Moderate Buy$25.69142.33% Upside
ODTX
Odyssey Therapeutics
2.67
Moderate Buy$37.0094.74% Upside

Current Analyst Ratings Breakdown

Latest IFRX, KURA, ODTX, and ALMS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2026
ODTX
Odyssey Therapeutics
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$42.00
10/8/2026
ODTX
Odyssey Therapeutics
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$42.00
10/5/2026
Alumis Inc. stock logo
ALMS
Alumis
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
10/5/2026
Alumis Inc. stock logo
ALMS
Alumis
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
10/5/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
10/2/2026
Alumis Inc. stock logo
ALMS
Alumis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/1/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$30.00
9/21/2026
InflaRx N.V. stock logo
IFRX
InflaRx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/16/2026
Alumis Inc. stock logo
ALMS
Alumis
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/14/2026
InflaRx N.V. stock logo
IFRX
InflaRx
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$8.00
9/3/2026
Alumis Inc. stock logo
ALMS
Alumis
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Neutral
(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alumis Inc. stock logo
ALMS
Alumis
$24.05M38.53N/AN/A$2.88 per share2.49
InflaRx N.V. stock logo
IFRX
InflaRx
$30K7,859.73N/AN/A$0.65 per share2.46
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$67.48M13.97N/AN/A$2.00 per share5.30
ODTX
Odyssey Therapeutics
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alumis Inc. stock logo
ALMS
Alumis
-$243.32M-$3.86N/AN/AN/A-5,933.46%-93.15%-74.50%11/12/2026 (Estimated)
InflaRx N.V. stock logo
IFRX
InflaRx
-$51.63M-$0.58N/AN/AN/AN/A-53.56%-43.02%11/9/2026 (Estimated)
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$278.67M-$3.37N/AN/AN/A-384.30%-207.18%-45.17%11/3/2026 (Estimated)
ODTX
Odyssey Therapeutics
N/A-$6.77N/AN/AN/AN/AN/AN/AN/A

Latest IFRX, KURA, ODTX, and ALMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/3/2026Q3 2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$0.8144N/AN/AN/A$23.81 millionN/A
8/13/2026Q2 2026
Alumis Inc. stock logo
ALMS
Alumis
-$0.7670-$1.11-$0.3430-$1.11$3.65 million$1.66 million
8/12/2026Q2 2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$0.8773-$0.77+$0.1073-$0.77$20.16 million$20.87 million
8/7/2026Q2 2026
InflaRx N.V. stock logo
IFRX
InflaRx
-$0.0666-$0.11-$0.0434-$0.10$0.01 millionN/A
8/5/2026Q2 2026
ODTX
Odyssey Therapeutics
N/A-$1.74N/A-$1.74N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alumis Inc. stock logo
ALMS
Alumis
N/AN/AN/AN/AN/A
InflaRx N.V. stock logo
IFRX
InflaRx
N/AN/AN/AN/AN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/AN/AN/AN/AN/A
ODTX
Odyssey Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alumis Inc. stock logo
ALMS
Alumis
N/A
6.74
6.74
InflaRx N.V. stock logo
IFRX
InflaRx
N/A
8.22
8.22
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
0.12
4.73
4.71
ODTX
Odyssey Therapeutics
N/A
11.36
11.36

Institutional Ownership

CompanyInstitutional Ownership
Alumis Inc. stock logo
ALMS
Alumis
N/A
InflaRx N.V. stock logo
IFRX
InflaRx
42.39%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/A
ODTX
Odyssey Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Alumis Inc. stock logo
ALMS
Alumis
33.70%
InflaRx N.V. stock logo
IFRX
InflaRx
16.30%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
7.60%
ODTX
Odyssey Therapeutics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Alumis Inc. stock logo
ALMS
Alumis
239129.43 million85.82 millionN/A
InflaRx N.V. stock logo
IFRX
InflaRx
65147.37 million123.35 millionOptionable
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
26088.96 million82.20 millionOptionable
ODTX
Odyssey Therapeutics
10048.06 millionN/AN/A

Recent News About These Companies

Odyssey Therapeutics (NASDAQ:ODTX) Upgraded at Raymond James Financial
October 10 at 7:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-odyssey-therapeutics-nasdaq-odtx-upgraded-at-raymond-james-financial-2026-10-10/
Raymond James initiates coverage of Odyssey Therapeutics with outperform
October 9 at 12:47 AM  |  msn.comhttps://www.msn.com/en-us/news/other/raymond-james-initiates-coverage-of-odyssey-therapeutics-with-outperform/ar-AA2dUzg0
Odyssey Therapeutics Inc (ODTX)
October 9 at 2:45 PM  |  investing.comhttps://www.investing.com/equities/odyssey-therapeutics-inc-ratios
Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375422/0/en/odyssey-therapeutics-announces-oral-presentation-of-additional-phase-2a-induction-data-for-od-001-in-ulcerative-colitis-at-ueg-week-2026.html
Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Stock Rated "Moderate Buy" by Sell-Side Analysts
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31085931
Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Stock Has Consensus Target Price of $35.75 According to Brokerages
October 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-odyssey-therapeutics-inc-nasdaq-odtx-stock-has-consensus-target-price-of-3575-according-to-brokerages-2026-10-05/
State Street Corp Makes New $1.48 Million Investment in Odyssey Therapeutics, Inc. $ODTX
September 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-state-street-corp-makes-new-148-million-investment-in-odyssey-therapeutics-inc-odtx-2026-09-27/
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
September 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/16/3363124/0/en/odyssey-therapeutics-to-participate-in-stifel-2026-virtual-immunology-and-inflammation-forum.html
Odyssey Therapeutics (ODTX) Banks Two More Years As Trials Multiply
September 13, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/odyssey-therapeutics-odtx-banks-two-more-years-as-trials-multiply-1837169/
Odyssey Therapeutics to Participate in Upcoming Investor Conferences
August 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/26/3351300/0/en/odyssey-therapeutics-to-participate-in-upcoming-investor-conferences.html
Odyssey Therapeutics Inc.
August 18, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/odtx/financials
Odyssey Therapeutics: Q2 Earnings Snapshot
August 6, 2026  |  chron.comhttps://www.chron.com/business/article/odyssey-therapeutics-q2-earnings-snapshot-22376823.php
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
August 6, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/evotec-and-odyssey-therapeutics-enter-ai-enabled-rd-collaboration-in-autoimmune-and-inflammatory-diseases-302844665.html
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/04/3338150/0/en/odyssey-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-update.html
Odyssey Therapeutics Stock Price History
July 16, 2026  |  investing.comhttps://www.investing.com/equities/odyssey-therapeutics-inc-historical-data
Odyssey Therapeutics Inc ODTX
July 8, 2026  |  morningstar.comM
Odyssey Therapeutics Inc ODTX
July 8, 2026  |  morningstar.comM
Odyssey Therapeutics Inc Share Price (ODTX.US)
July 6, 2026  |  lse.co.ukhttps://www.lse.co.uk/SharePrice.html?shareprice=ODTX.US
Odyssey Therapeutics: Q1 Earnings Snapshot
June 18, 2026  |  chron.comhttps://www.chron.com/business/article/odyssey-therapeutics-q1-earnings-snapshot-22310114.php
Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
June 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/17/3313811/0/en/odyssey-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update.html
Odyssey Therapeutics Inc
May 26, 2026  |  money.usnews.comhttps://money.usnews.com/investing/stocks/odtx-odyssey-therapeutics-inc

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alumis stock logo

Alumis NASDAQ:ALMS

$7.16 +0.19 (+2.73%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$7.09 -0.07 (-0.98%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

InflaRx stock logo

InflaRx NASDAQ:IFRX

$1.60 +0.07 (+4.58%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$1.60 -0.01 (-0.31%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Kura Oncology stock logo

Kura Oncology NASDAQ:KURA

$10.60 +0.08 (+0.76%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$10.61 +0.01 (+0.09%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Odyssey Therapeutics NASDAQ:ODTX

$19.00 +0.88 (+4.86%)
As of 10/9/2026 04:00 PM Eastern

Odyssey Therapeutics Inc. is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc. is based in BOSTON.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas